Markets:

Overview

News

Currencies

International

Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

18.11 +0.26 (+1.46%)

Streaming Delayed Price Updated: 1:13 PM EST, Jan 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy ↗

March 25, 2022

The European Medicines Agency's CHMP

Via Benzinga

CARVYKTI® (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

March 25, 2022

From Legend Biotech

Via Business Wire

Flanders Investment and Trade Names Legend Biotech Newcomer of the Year

March 23, 2022

From Legend Biotech

Via Business Wire

Legend Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

March 18, 2022

From Legend Biotech

Via Business Wire

Analyst Ratings For Legend Biotech ↗

March 15, 2022

Analysts have provided the following ratings for Legend Biotech (NASDAQ:LEGN) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022 ↗

March 15, 2022

Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 14, 2022

Gainers Erytech Pharma (NASDAQ:ERYP) stock rose 18.7% to $1.65 during Monday's pre-market session. The market value of their outstanding shares is at $51.1 million....

Via Benzinga

The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg ↗

March 06, 2022

Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (...

Via Benzinga

Week In Review: Adagene Forms $2.5 Billion, Four-Drug Partnership With Sanofi ↗

March 05, 2022

Adagene will apply its technology to as many as four Sanofi candidates in a collaboration worth up to $2.5 billion. Huadong Medicine will acquire Asia rights for two Heidelberg Pharma ADC candidates in...

Via Talk Markets

GenScript Losses Widen, But Investors Focus on Newly Approved Cancer Treatment ↗

March 01, 2022

Key takeaways: GenScript Biotech said it lost up to $519 million last year, with its Legend Biotech unit accounting for nearly 70% of that Legend Biotech’s Cilta-cel CAR-T...

Via Benzinga

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution ↗

March 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...

Via Benzinga

FDA Approves JNJ-Legend Biotech Partnered Blood Cancer Therapy ↗

March 01, 2022

The FDA has approved Legend Biotech Corporation's (NASDAQ: LEGN) first product, Carvykti (ciltacabtagene autoleucel; cilta-cel), for relapsed or refractory...

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the...

Via Talk Markets

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

Week In Review: AffaMed Announced US Approval To Start Clinical Trials ↗

February 19, 2022

AffaMed recently in-licensed ex-Asia (plus Japan) rights to a novel bispecific biologic molecule aimed at retinal vascular diseases from AskGene Pharma. On Saturday, AffaMed announced US approval to...

Via Talk Markets

Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2021

February 18, 2022

From Legend Biotech

Via Business Wire

FDA Slams Brakes On Legend Biotech's CAR-T Therapy Trial In Lymphoma Patients ↗

February 15, 2022

The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ: LEGN) Phase 1 trial for LB1901. LB1901 is the company's...

Via Benzinga

Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901

February 15, 2022

From Legend Biotech

Via Business Wire

Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen

February 11, 2022

From Legend Biotech

Via Business Wire

Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates ↗

February 01, 2022

After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned.

Via Benzinga

Legend Biotech to Participate in the 40th Annual J.P. Morgan Healthcare Conference

January 04, 2022

From Legend Biotech Corporation

Via Business Wire

Legend Biotech Announces Appointment of Dr. Ying Huang to the Board of Directors

December 30, 2021

From Legend Biotech Corporation

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022 ↗

January 31, 2022

Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago...

Via Benzinga

Legend Biotech Corporation Announces Pricing of Public Offering

December 16, 2021

From Legend Biotech Corporation

Via Business Wire

18 Stocks Moving in Thursday's Pre-Market Session ↗

December 16, 2021

Gainers Calliditas Therapeutics AB (NASDAQ: CALT) rose 36.5% to $25.45 in pre-market trading after the company announced it was granted by the FDA accelerated approval of TARPEYO...

Via Benzinga

46 Biggest Movers From Yesterday ↗

December 16, 2021

Gainers Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday. CMC Materials, Inc. (NASDAQ: CCMP) climbed 33.9% to close at $195.50 on...

Via Benzinga

36 Stocks Moving In Wednesday's Mid-Day Session ↗

December 15, 2021

Gainers Nxt-ID, Inc. (NASDAQ: NXTD) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

December 15, 2021

Gainers Gemini Therapeutics (NASDAQ:GMTX) shares moved upwards by 32.92% to $3.23 during Wednesday's pre-market session. The market value of their outstanding shares...

Via Benzinga

The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO ↗

December 15, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Vir Biotech Says COVID-19 Antibody Treatment Effective Against Omicron...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

December 15, 2021

We're at the halfway point of the week but there's no slowing down as we dive into the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.